bluebird bio (NASDAQ: BLUE) announced its fourth-quarter and full-year financial results on Tuesday afternoon. The clinical-stage biotech's stock price fell a bit in after-hours trading as investors reacted to the mixed report.
Although the company beat its revenue target, bluebird failed to hit Wall Street analysts' consensus estimate on earnings per share. The company reported total revenue of $10.0 million, the majority of which came from collaboration agreements. Although that was down substantially from the $19.2 million it reported in the prior-year period, it was still better than the $9.2 million expected by Wall Street analysts.
Image source: Getty Images